ARTV Fred Aslan sells $153K worth of shares
Oct 18, 2025, 4:37 AM
0.00%
What does ARTV do
Artiva Biotherapeutics, based in San Diego, focuses on NK cell-based therapies for autoimmune diseases and cancers, with its lead candidate AlloNK in Phase I/Ib trials. The company went public on July 19, 2024.
Fred Aslan sold 25,500 shares of ARTV on 17 October at $6.00 per share, worth a total of $153K. They now own 356,721 ARTV shares, or a 7% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
